Product Information
DARUNAVIR 800 MG TABLET is a generic product labeled by Cipla USA Inc., priced at $2.3819 per EA under NDC 69097024402. Its NADAC has been published 133 times since Mar 20, 2024.
FDA first approved this application on Nov 28, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
800 mg/1
Manufacturer
Cipla USA Inc.NDC
69097024402
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DARUNAVIR HYDRATEApproval Type
Generic (ANDA)
FDA Application
ANDA206288FDA Approved
11/28/2023
TE Code
AB
On Market Since
11/29/2023
Pharmacological Classes
Price Statistics
The NADAC for DARUNAVIR 800 MG TABLET has been published 133 times since Mar 20, 2024, and over the history we have for it it has declined 28.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.3819 per EA |
|---|---|
| All-time high | $3.6749 (Oct 16, 2024) |
| All-time low | $2.1216 (Apr 22, 2026) |
| 52-week high | $2.5220 |
| 52-week low | $2.1216 |
| Median price | $2.4982 |
| Average price | $2.6988 |
| Largest weekly change | +25.3% (Aug 21, 2024) |
| Weeks tracked | 133 |
| Tracking since | Mar 20, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cipla USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
darunavir market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Protease Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DARUNAVIR 800 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for DARUNAVIR 800 MG TABLET, manufactured by Cipla USA Inc., is $2.3819 per EA (NDC 69097024402), effective Sep 30, 2026.
How has the price of DARUNAVIR 800 MG TABLET changed over time?
Over the history we have for it, the NADAC for DARUNAVIR 800 MG TABLET has declined 28.2%. It has been tracked across 133 weekly CMS publications since Mar 20, 2024.
What are the highest and lowest recorded NADAC prices for DARUNAVIR 800 MG TABLET?
Since Mar 20, 2024, the NADAC for DARUNAVIR 800 MG TABLET has ranged from a low of $2.1216 (Apr 22, 2026) to a high of $3.6749 (Oct 16, 2024), with a median of $2.4982 per EA.
Are there cheaper alternatives to DARUNAVIR 800 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as DARUNAVIR 800 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures DARUNAVIR 800 MG TABLET?
DARUNAVIR 800 MG TABLET (NDC 69097024402) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.